228 related articles for article (PubMed ID: 32335861)
1. Tumor shedding and metastatic progression after tumor excision in patient-derived orthotopic xenograft models of triple-negative breast cancer.
Razmara AM; Sollier E; Kisirkoi GN; Baker SW; Bellon MB; McMillan A; Lemaire CA; Ramani VC; Jeffrey SS; Casey KM
Clin Exp Metastasis; 2020 Jun; 37(3):413-424. PubMed ID: 32335861
[TBL] [Abstract][Full Text] [Related]
2. Investigating circulating tumor cells and distant metastases in patient-derived orthotopic xenograft models of triple-negative breast cancer.
Ramani VC; Lemaire CA; Triboulet M; Casey KM; Heirich K; Renier C; Vilches-Moure JG; Gupta R; Razmara AM; Zhang H; Sledge GW; Sollier E; Jeffrey SS
Breast Cancer Res; 2019 Aug; 21(1):98. PubMed ID: 31462307
[TBL] [Abstract][Full Text] [Related]
3. The identification of a TNBC liver metastasis gene signature by sequential CTC-xenograft modeling.
Vishnoi M; Liu NH; Yin W; Boral D; Scamardo A; Hong D; Marchetti D
Mol Oncol; 2019 Sep; 13(9):1913-1926. PubMed ID: 31216110
[TBL] [Abstract][Full Text] [Related]
4. p53 deficiency linked to B cell translocation gene 2 (BTG2) loss enhances metastatic potential by promoting tumor growth in primary and metastatic sites in patient-derived xenograft (PDX) models of triple-negative breast cancer.
Powell E; Shao J; Yuan Y; Chen HC; Cai S; Echeverria GV; Mistry N; Decker KF; Schlosberg C; Do KA; Edwards JR; Liang H; Piwnica-Worms D; Piwnica-Worms H
Breast Cancer Res; 2016 Jan; 18(1):13. PubMed ID: 26818199
[TBL] [Abstract][Full Text] [Related]
5. Response of Triple-negative Breast Cancer Liver Metastasis to Oral Recombinant Methioninase in a Patient-derived Orthotopic Xenograft (PDOX) Model.
Lim HI; Yamamoto J; Han Q; Sun YU; Nishino H; Tashiro Y; Sugisawa N; Tan Y; Choi HJ; Nam SJ; Bouvet M; Hoffman RM
In Vivo; 2020; 34(6):3163-3169. PubMed ID: 33144420
[TBL] [Abstract][Full Text] [Related]
6. A Single Low Dose of Eribulin Regressed a Highly Aggressive Triple-negative Breast Cancer in a Patient-derived Orthotopic Xenograft Model.
Lim HI; Yamamoto J; Inubushi S; Nishino H; Tashiro Y; Sugisawa N; Han Q; Sun YU; Choi HJ; Nam SJ; Kim MB; Lee JS; Hozumi C; Bouvet M; Singh SR; Hoffman RM
Anticancer Res; 2020 May; 40(5):2481-2485. PubMed ID: 32366392
[TBL] [Abstract][Full Text] [Related]
7. A Triple-negative Matrix-producing Breast Carcinoma Patient-derived Orthotopic Xenograft (PDOX) Mouse Model Is Sensitive to Bevacizumab and Vinorelbine, Regressed by Eribulin and Resistant to Olaparib.
Yamamoto J; Murata T; Tashiro Y; Higuchi T; Sugisawa N; Nishino H; Inubushi S; Sun YU; Lim H; Miyake K; Hongo A; Nomura T; Saitoh W; Moriya T; Tanino H; Hozumi C; Bouvet M; Singh SR; Endo I; Hoffman RM
Anticancer Res; 2020 May; 40(5):2509-2514. PubMed ID: 32366395
[TBL] [Abstract][Full Text] [Related]
8. Nuclear-Biased DUSP6 Expression is Associated with Cancer Spreading Including Brain Metastasis in Triple-Negative Breast Cancer.
Wu F; McCuaig RD; Sutton CR; Tan AHY; Jeelall Y; Bean EG; Dai J; Prasanna T; Batham J; Malik L; Yip D; Dahlstrom JE; Rao S
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31238530
[TBL] [Abstract][Full Text] [Related]
9. Eribulin Regresses a Cisplatinum-resistant Rare-type Triple-negative Matrix-producing Breast Carcinoma Patient-derived Orthotopic Xenograft Mouse Model.
Yamamoto J; Murata T; Sugisawa N; Higuchi T; Tashiro Y; Nishino H; Inubushi S; Sun YU; Lim H; Miyake K; Shimoya K; Nomura T; Kurebayashi J; Tanino H; Hozumi C; Bouvet M; Singh SR; Endo I; Hoffman RM
Anticancer Res; 2020 May; 40(5):2475-2479. PubMed ID: 32366391
[TBL] [Abstract][Full Text] [Related]
10. Cancer Testis Antigen Promotes Triple Negative Breast Cancer Metastasis and is Traceable in the Circulating Extracellular Vesicles.
Kannan A; Philley JV; Hertweck KL; Ndetan H; Singh KP; Sivakumar S; Wells RB; Vadlamudi RK; Dasgupta S
Sci Rep; 2019 Aug; 9(1):11632. PubMed ID: 31406142
[TBL] [Abstract][Full Text] [Related]
11. Leptin produced by obesity-altered adipose stem cells promotes metastasis but not tumorigenesis of triple-negative breast cancer in orthotopic xenograft and patient-derived xenograft models.
Sabol RA; Bowles AC; Côté A; Wise R; O'Donnell B; Matossian MD; Hossain FM; Burks HE; Del Valle L; Miele L; Collins-Burow BM; Burow ME; Bunnell BA
Breast Cancer Res; 2019 May; 21(1):67. PubMed ID: 31118047
[TBL] [Abstract][Full Text] [Related]
12. A Case of Rare Matrix-producing Triple-negative Breast Carcinoma for Which Drug Response in a Patient-derived Orthotopic Xenograft Mouse Model Was Correlated With Patient Response.
Nomura T; Kurebayashi J; Moriya T; Saito W; Murata T; Yamamoto J; Hozumi C; Hoffman RM
Anticancer Res; 2021 Dec; 41(12):6191-6197. PubMed ID: 34848473
[TBL] [Abstract][Full Text] [Related]
13. Identification of ALDH1A3 as a Viable Therapeutic Target in Breast Cancer Metastasis-Initiating Cells.
Yamashita D; Minata M; Ibrahim AN; Yamaguchi S; Coviello V; Bernstock JD; Harada S; Cerione RA; Tannous BA; La Motta C; Nakano I
Mol Cancer Ther; 2020 May; 19(5):1134-1147. PubMed ID: 32127468
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Oral Recombinant Methioninase and Eribulin on a PDOX Model of Triple-negative Breast Cancer (TNBC) Liver Metastasis.
Lim HI; Sun YU; Han Q; Yamamoto J; Hoffman RM
In Vivo; 2021; 35(5):2531-2534. PubMed ID: 34410939
[TBL] [Abstract][Full Text] [Related]
15. EGFR inhibition blocks cancer stem cell clustering and lung metastasis of triple negative breast cancer.
Liu X; Adorno-Cruz V; Chang YF; Jia Y; Kawaguchi M; Dashzeveg NK; Taftaf R; Ramos EK; Schuster EJ; El-Shennawy L; Patel D; Zhang Y; Cristofanilli M; Liu H
Theranostics; 2021; 11(13):6632-6643. PubMed ID: 33995681
[TBL] [Abstract][Full Text] [Related]
16. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states.
Yoshida T; Ozawa Y; Kimura T; Sato Y; Kuznetsov G; Xu S; Uesugi M; Agoulnik S; Taylor N; Funahashi Y; Matsui J
Br J Cancer; 2014 Mar; 110(6):1497-505. PubMed ID: 24569463
[TBL] [Abstract][Full Text] [Related]
17. Circulating tumor cells in non-metastatic triple-negative breast cancer.
Karhade M; Hall C; Mishra P; Anderson A; Kuerer H; Bedrosian I; Krishnamurthy S; Lucci A
Breast Cancer Res Treat; 2014 Sep; 147(2):325-33. PubMed ID: 25164970
[TBL] [Abstract][Full Text] [Related]
18. CTCs-derived xenograft development in a triple negative breast cancer case.
Pereira-Veiga T; Abreu M; Robledo D; Matias-Guiu X; Santacana M; Sánchez L; Cueva J; Palacios P; Abdulkader I; López-López R; Muinelo-Romay L; Costa C
Int J Cancer; 2019 May; 144(9):2254-2265. PubMed ID: 30450632
[TBL] [Abstract][Full Text] [Related]
19. Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model.
Cheng RYS; Patel NL; Back T; Basudhar D; Somasundaram V; Kalen JD; Wink DA; Ridnour LA
J Vis Exp; 2020 Mar; (157):. PubMed ID: 32250353
[TBL] [Abstract][Full Text] [Related]
20. MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer.
Greer YE; Gilbert SF; Gril B; Narwal R; Peacock Brooks DL; Tice DA; Steeg PS; Lipkowitz S
Breast Cancer Res; 2019 Feb; 21(1):27. PubMed ID: 30777098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
